Zhang XinYuan, Liu Wei, Wu ShanShan, Jin JingLong, Li WeiHong, Wang NingLi
Beijing Institute of Ophthalmology, Tongren Eye Centre, Tongren Hospital, Capital Medical University, Beijing, 100730, China,
Sci China Life Sci. 2015 Jan;58(1):101-7. doi: 10.1007/s11427-014-4792-1. Epub 2014 Dec 20.
Many randomized clinical controlled trials have confirmed the efficacy and safety of calcium dobesilate in treating diabetic retinopathy (DR). This systematic review critically evaluated the evidence that links calcium dobesilate to DR. In this fixed-effects meta-analysis, a total of 221 pertinent English-language articles published between January 1975 and October 2013 were identified. Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were conducted using the keywords "diabetic retinopathy" and "calcium dobesilate". The extracted information included the study design, inclusion and exclusion criteria, setting, sample size, participant mean age, treatment regime, mean change in best corrected visual acuity, laboratory parameters, capillary fragility, intraocular pressure and fundus manifestations based on the findings of fluorescent angiography. The summary statistics indicated that calcium dobesilate was significantly associated with improving retinal microaneurysms (RR: 0.62, 95%CI: 0.42-0.90, P=0.01), retinal hemorrhages (RR: 0.39, 95% CI: 0.17-0.88, P=0.02); exudates (RR: 0.31, 95% CI: 0.12-0.81, P=0.02), reduction of whole blood viscosity (MD: -0.57 CP, 95% CI: -0.75 to -0.38, P<0.001), plasma viscosity (MD: -0.36 CP, 95% CI: -0.63 to -0.09, P=0.01) and blood cholesterol (MD: -0.48 mg mL(-1), 95% CI: -0.64-0.33, P<0.00001). Intraocular pressure was also significantly reduced (MD: -5.59 mmHg, 95% CI: -6.69 to -4.50, P<0.00001). The results indicate that calcium dobesilate effectively treats DR at the systematic and local ocular levels.
许多随机临床对照试验已证实羟苯磺酸钙治疗糖尿病视网膜病变（DR）的有效性和安全性。本系统评价严格评估了将羟苯磺酸钙与DR联系起来的证据。在这项固定效应荟萃分析中，共识别出1975年1月至2013年10月期间发表的221篇相关英文文章。使用关键词“糖尿病视网膜病变”和“羟苯磺酸钙”对PUBMED、Springer Link和Cochrane临床试验数据库进行了系统检索。提取的信息包括研究设计、纳入和排除标准、研究背景、样本量、参与者平均年龄、治疗方案、最佳矫正视力的平均变化、实验室参数、毛细血管脆性、眼压以及基于荧光血管造影结果的眼底表现。汇总统计表明，羟苯磺酸钙与改善视网膜微动脉瘤（RR：0.62，95%CI：0.42 - 0.90，P = 0.01）、视网膜出血（RR：0.39，95%CI：0.17 - 0.88，P = 0.02）、渗出物（RR：0.31，95%CI：0.12 - 0.81，P = 0.02）、降低全血粘度（MD：-0.57 CP，95%CI：-0.75至-0.38，P < 0.001）、血浆粘度（MD：-0.36 CP，95%CI：-0.63至-0.09，P = 0.01）和血胆固醇（MD：-0.48 mg mL(-1)，95%CI：-0.64 - 0.33，P < 0.00001）显著相关。眼压也显著降低（MD：-5.59 mmHg，95%CI：-6.69至-4.50，P < 0.00001）。结果表明，羟苯磺酸钙在全身和局部眼部水平上均能有效治疗DR。
